Publications by authors named "Mayte Gil Candel"
Objectives: This study aimed to describe the actions taken to implement a telepharmacy programme with home medication dispensing and informed delivery in an outpatient pharmaceutical care unit of a tertiary hospital, where approximately 5000 patients are treated per year. It also aimed to substantiate the applicability and benefits of the programme through analysing the findings and measuring patient satisfaction.
Methods: We identified the operational, logistical, technological and legal needs, as well as the need for training, information and coordination with the care team and patient associations.
Introduction: numerous studies have shown a positive correlation between serum biologic drug concentrations and favorable therapeutic outcomes during the induction and maintenance period in patients with Crohn's disease (CD). To our knowledge, only a few and contradictory studies have determined the association between ustekinumab (UST) trough concentrations and biological outcomes. This study aimed to investigate the relationship between ustekinumab trough concentrations and biological outcomes in a real-world setting.
View Article and Find Full Text PDFIntroduction: infliximab is used in inflammatory bowel disease, which has a great inter-individual pharmacokinetic variability. Thus, it is necessary to individualize the therapy in many cases. The main objective of our study was to compare two methods of a dose adjustment strategy using therapeutic drug monitoring: a) based on an algorithm and b) based on Bayesian prediction, to achieve an optimal infliximab trough level in patients with inflammatory bowel diseases.
View Article and Find Full Text PDFArticle Synopsis
- Higher infliximab trough levels are linked to better outcomes for patients with inflammatory bowel disease, prompting the need for proactive drug monitoring during the induction phase.
- In a study of 30 patients, only 43.3% reached target infliximab levels after six weeks, with those achieving higher levels showing significantly better clinical and biochemical responses by week 26.
- The findings suggest that therapeutic drug monitoring could be crucial for improving treatment effectiveness during the early stages of infliximab therapy.
Article Synopsis
- This study reviews how treatment with biological agents for inflammatory bowel disease, specifically infliximab and adalimumab, compares over time in a cohort of patients treated between 2008 and 2017 at a hospital in Spain.
- Results showed that the average duration patients maintained their treatment was similar for both drugs, with adalimumab slightly outperforming infliximab in first- and second-line settings, although the difference was not statistically significant.
- The only factor linked to longer drug survival was therapeutic drug monitoring, suggesting that closely tracking medication levels may enhance treatment effectiveness for patients.